Drug Profile
Influenza vaccine quadrivalent - Seqirus
Alternative Names: Afluria Quad; AFLURIA QUADRIVALENT; aQIV; CSL QIV; Influenza vaccine quadrivalent - bioCSL; Quadrivalent influenza vaccine - (CSL-QIV); Quadrivalent influenza vaccine - bioCSL; Quadrivalent influenza vaccine - Seqirus; Seqirus QIV; Split virion inactivated quadrivalent influenza vaccine - bioCSLLatest Information Update: 10 Nov 2023
Price :
$50
*
At a glance
- Originator bioCSL
- Developer Seqirus
- Class Influenza virus vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Influenza virus infections
Most Recent Events
- 23 Oct 2023 Seqirus initiates enrolment in a phase III trial for Influenza virus infections (Prevention) in Belgium (NCT06087640)
- 07 Dec 2022 No development reported - Phase-III for Influenza virus infections (In children, In infants, Prevention) in Canada (IM) (NCT01964989)
- 07 Dec 2022 No development reported - Phase-III for Influenza virus infections (In children, In infants, Prevention) in Finland (IM) (NCT01964989)